These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 31309775)

  • 21. Iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis and the quality of life: a new therapeutic protocol.
    Milio G; Corrado E; Genova C; Amato C; Raimondi F; Almasio PL; Novo S
    Rheumatology (Oxford); 2006 Aug; 45(8):999-1004. PubMed ID: 16484290
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term treatment of scleroderma-related digital ulcers with iloprost: a cohort study.
    Colaci M; Lumetti F; Giuggioli D; Guiducci S; Bellando-Randone S; Fiori G; Matucci-Cerinic M; Ferri C
    Clin Exp Rheumatol; 2017; 35 Suppl 106(4):179-183. PubMed ID: 28980901
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers.
    Abou-Raya A; Abou-Raya S; Helmii M
    J Rheumatol; 2008 Sep; 35(9):1801-8. PubMed ID: 18709692
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Treatment of therapy-resistant acral ulcers with iloprost].
    von Schmiedeberg S; Artik S; Assmann T; Megahed M; Ruzicka T
    Hautarzt; 2004 Dec; 55(12):1150-3. PubMed ID: 15568132
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of treatment with iloprost with or without bosentan on nailfold videocapillaroscopic alterations in patients with systemic sclerosis.
    Cestelli V; Manfredi A; Sebastiani M; Praino E; Cannarile F; Giuggioli D; Ferri C
    Mod Rheumatol; 2017 Jan; 27(1):110-114. PubMed ID: 27310203
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oral iloprost in Raynaud's phenomenon secondary to systemic sclerosis: a multicentre, placebo-controlled, dose-comparison study.
    Black CM; Halkier-Sørensen L; Belch JJ; Ullman S; Madhok R; Smit AJ; Banga JD; Watson HR
    Br J Rheumatol; 1998 Sep; 37(9):952-60. PubMed ID: 9783759
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A novel iloprost administration method with portable syringe pump for the treatment of acral ulcers and Raynaud's phenomenon in systemic sclerosis patients. A pilot study (ILOPORTA).
    Fraticelli P; Martino GP; Murri M; Mattioli M; Gabrielli A
    Clin Exp Rheumatol; 2017; 35 Suppl 106(4):173-178. PubMed ID: 28869415
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Effects of long-term iloprost therapy on Raynaud's phenomenon in progressive systemic sclerosis].
    Cordioli E; Virgilio S; Ghirardi R; Martinelli M
    Minerva Med; 1992 Nov; 83(11):739-44. PubMed ID: 1281297
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study.
    Rademaker M; Cooke ED; Almond NE; Beacham JA; Smith RE; Mant TG; Kirby JD
    BMJ; 1989 Mar; 298(6673):561-4. PubMed ID: 2467711
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics of oral iloprost in patients with Raynaud's phenomenon secondary to systemic sclerosis.
    Janssena MC; Wollersheim H; Kraus C; Hildebrand M; Watson HR; Thien T
    Prostaglandins Other Lipid Mediat; 2000 Mar; 60(4-6):153-60. PubMed ID: 10751645
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cyclosporin A and iloprost treatment of systemic sclerosis: clinical results and interleukin-6 serum changes after 12 months of therapy.
    Filaci G; Cutolo M; Scudeletti M; Castagneto C; Derchi L; Gianrossi R; Ropolo F; Zentilin P; Sulli A; Murdaca G; Ghio M; Indiveri F; Puppo F
    Rheumatology (Oxford); 1999 Oct; 38(10):992-6. PubMed ID: 10534551
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of five-day versus one-day infusion of iloprost on the peripheral microcirculation in patients with systemic sclerosis.
    Ceru S; Pancera P; Sansone S; Sfondrini G; Codella O; De Sandre G; Lechi A; Lunardi C
    Clin Exp Rheumatol; 1997; 15(4):381-5. PubMed ID: 9272298
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evidence for increase in finger blood flow, evaluated by laser Doppler flowmetry, following iloprost infusion in patients with systemic sclerosis: a week-long observational longitudinal study.
    Rotondo C; Nivuori M; Chialà A; Praino E; Matucci Cerinic M; Cutolo M; Lapadula G; Iannone F
    Scand J Rheumatol; 2018 Jul; 47(4):311-318. PubMed ID: 29409385
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vasoactive Therapy in Systemic Sclerosis: Real-life Therapeutic Practice in More Than 3000 Patients.
    Moinzadeh P; Riemekasten G; Siegert E; Fierlbeck G; Henes J; Blank N; Melchers I; Mueller-Ladner U; Frerix M; Kreuter A; Tigges C; Lahner N; Susok L; Guenther C; Zeidler G; Pfeiffer C; Worm M; Karrer S; Aberer E; Bretterklieber A; Genth E; Simon JC; Distler JH; Hein R; Schneider M; Seitz CS; Herink C; Steinbrink K; Sárdy M; Varga R; Mensing H; Mensing C; Lehmann P; Neeck G; Fiehn C; Weber M; Goebeler M; Burkhardt H; Buslau M; Ahmadi-Simab K; Himsel A; Juche A; Koetter I; Kuhn A; Sticherling M; Hellmich M; Kuhr K; Krieg T; Ehrchen J; Sunderkoetter C; Hunzelmann N;
    J Rheumatol; 2016 Jan; 43(1):66-74. PubMed ID: 26568599
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Iloprost administration over 21 days as an effective therapy in systemic scleroderma--case report and review of the literature].
    Riemekasten G; Jepsen H; Burmester GR; Hiepe F
    Z Rheumatol; 1998 Apr; 57(2):118-24. PubMed ID: 9627952
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antioxidant status after iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis.
    Balbir-Gurman A; Braun-Moscovici Y; Livshitz V; Schapira D; Markovits D; Rozin A; Boikaner T; Nahir AM
    Clin Rheumatol; 2007 Sep; 26(9):1517-21. PubMed ID: 17401513
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Social/economic costs and health-related quality of life in patients with scleroderma in Europe.
    López-Bastida J; Linertová R; Oliva-Moreno J; Serrano-Aguilar P; Posada-de-la-Paz M; Kanavos P; Taruscio D; Schieppati A; Iskrov G; Péntek M; Delgado C; von der Schulenburg JM; Persson U; Chevreul K; Fattore G;
    Eur J Health Econ; 2016 Apr; 17 Suppl 1():109-17. PubMed ID: 27038626
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Iloprost for the treatment of systemic sclerosis].
    Hachulla E; Launay D; Hatron PY
    Presse Med; 2008 May; 37(5 Pt 2):831-9. PubMed ID: 18035518
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Health-related quality of life in patients with systemic sclerosis: evolution over time and main determinants.
    van Leeuwen NM; Ciaffi J; Liem SIE; Huizinga TWJ; de Vries-Bouwstra JK
    Rheumatology (Oxford); 2021 Aug; 60(8):3646-3655. PubMed ID: 33401302
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis.
    Thompson AE; Shea B; Welch V; Fenlon D; Pope JE
    Arthritis Rheum; 2001 Aug; 44(8):1841-7. PubMed ID: 11508437
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.